Tetra Pak, Hamlet Pharma and Linnane Pharma have signed a Letter of Intent regarding the development of consumer products
Hamlet and Tetra Pak wish to explore the possibilities to include into food products the active complex (The-A-complex) formed by bovine alpha-lactalbumin and oleic acid (formerly named BAMLET).
The objective is to allow Tetra Pak´s customers or other producers of products to include The-A-complex as an ingredient, enabling potential future claims on benefits generated by the active complex. The processing technology and solutions will be sourced from Tetra Pak, the patent rights from Hamlet Pharma and the background scientific and small scale manufacturing know-how from Linnane Pharma, which will provide continued scientific support during the development process. The parties are further committed to exploring a mutual commercial agreement during the product validation process.
Importantly, HAMLET Pharma retains the patent rights to the “BAMLET complex”, which is being developed separately for pharmaceutical use.
‘’We are delighted to initiate this exciting development with the aim to commercialize an important part of our patent family’’, says Hamlet Pharma
‘’The-A-complex has important promise as an active component with the potential of a improving a range of food products,’’ says Tetra Pak
This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 07-06-2021 15:48 CET.
For more information, please contact
Catharina Svanborg, Chairperson of the board, Hamlet Pharma, +46 709 42 65 49
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.
This project is funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 954360.